Big Pharma, with eye on Anthropic, says AI is shrinking drug discovery timelines
AI is revolutionizing early-stage drug development for major pharmaceutical companies, cutting the time required to create new molecules and bring them to the clinic by up to half, according to top scientists. Companies such as GSK, Bristol Myers Squibb, Novartis, Eli Lilly, Novo Nordisk, AstraZeneca, and Sanofi have moved beyond using AI for preparing regulatory filings, and now employ it for designing molecules, evaluating the most promising ones, and identifying safety risks.
AstraZeneca's Sharon Barr stated that AI is now utilized in every stage of the discovery through development pipeline.
While AI companies like Anthropic aim to become rivals, partners, or both, drug companies remain cautious about Anthropic's potential. Anthropic CEO Dario Amodei, speaking at Nasdaq, mentioned his personal loss and optimism about AI accelerating processes to find cures for diseases. However, some pharmaceutical executives, like Lilly's Aliza Apple, argue that such claims are exaggerated and that AI's current capabilities are limited.
Despite the optimism, the number of AI-enabled drugs in clinical testing has only increased gradually. In March, there were 129 drug candidates across 69 companies, up from around 117 eight months earlier, with most programs still in early-stage development. Dr. Waqas Haque, an oncology fellow, expects to see a sharp increase in AI drugs being developed pre-clinically and going to clinical trials in the next 1-3 years, though he doubts they will be approved any quicker than non-AI drugs due to bottlenecks in human trials and regulators.
Companies like Novartis and Novo Nordisk have already seen concrete results from AI in drug development. Novartis found five targets prioritized for kidney disease treatments, while Novo Nordisk cut the number of cycles of designing, manufacturing, and testing new molecules from around eight to three, and reduced the time for each cycle from eight weeks to four. However, Anthropic and other AI rivals are seeking partnerships and acquisitions in the pharma industry, driven by the desire for more data and companies.
Written by urgent.news from Channel News Asia's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Big Pharma, with eye on Anthropic, says AI is shrinking drug discovery timelines channelnewsasia.com